Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKitoh, H.en
dc.contributor.authorAchiwa, M.en
dc.contributor.authorKaneko, H.en
dc.contributor.authorMishima, K.en
dc.contributor.authorMatsushita, M.en
dc.contributor.authorKadono, I.en
dc.contributor.authorHorowitz, J.en
dc.contributor.authorSallustio, B.en
dc.contributor.authorOhno, K.en
dc.contributor.authorIshiguro, N.en
dc.identifier.citationOrphanet Journal of Rare Diseases, 2013; 8(1):163-1-163-7en
dc.description.abstractBackground: Currently, there are no effective medical treatment options to prevent the formation of heterotopic bones in fibrodysplasia ossificans progressiva (FOP). By the drug repositioning strategy, we confirmed that perhexiline maleate (Pex) potentially ameliorates heterotopic ossification in model cells and mice. Here, we conducted a prospective study to assess the efficacy and safety of Pex in the treatment of FOP patients. Methods: FOP patients in this open-label single-center study were treated with Pex for a total of 12 months, and followed up for 12 consecutive months after medication discontinuation. The safety of the treatment was assessed regularly by physical and blood examinations. The efficacy of Pex for preventing heterotopic ossifications was evaluated by the presence of flare-ups, measurements of serum bone markers, and changes in the total bone volume calculated by the three-dimensional computed tomography (3D-CT) images. Results: Five patients with an average age of 23.4 years were enrolled. Within safe doses of Pex administration in each individual, there were no drug-induced adverse effects during the medication phase. Three patients showed no intense inflammatory reactions during the study period, while two patients had acute flare-ups around the hip joint without evidence of trauma during the medication phase. In addition, one of them became progressively incapable of opening her mouth over the discontinuation phase. Serum levels of alkaline phosphatase (ALP) and bone specific ALP (BAP) were significantly and synchronously increased with the occurrence of flare-ups. Volumetric 3D-CT analysis demonstrated a significant increase in the total bone volume of Case 2 (378 cm³) and Case 3 (833 cm³) during the two-year study period. Conclusions: We could not prove the efficacy of oral Pex administration in the prevention of heterotopic ossifications in FOP. Serum levels of ALP and BAP appear to be promising biomarkers for monitoring the development of ectopic ossifications and efficacy of the therapy. Quantification of change in the total bone volume by whole body CT scanning could be a reliable evaluation tool for disease progression in forthcoming clinical trials of FOP.en
dc.description.statementofresponsibilityHiroshi Kitoh, Masataka Achiwa, Hiroshi Kaneko, Kenichi Mishima, Masaki Matsushita, Izumi Kadono, John D Horowitz, Benedetta C Sallustio, Kinji Ohno and Naoki Ishiguroen
dc.publisherBioMed Centralen
dc.rights© 2013 Kitoh et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.subjectFibrodysplasia ossificans progressive; perhexiline maleate; clinical trial; biomarker; whole body CTen
dc.titlePerhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trialen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]en
dc.identifier.orcidSallustio, B. [0000-0002-0186-3073]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_112318.pdfPublished version924.05 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.